Skip to content
Xenon xe 127
Xenon xe 127 is a small molecule pharmaceutical. Xenon xe 127 was first approved as Xenon xe 127 on 1982-10-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Xenon xe-127
Tradename
Company
Number
Date
Products
XENON XE 127MallinckrodtN-018536 DISCN1982-10-01
2 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
xenoviewNew Drug Application2022-12-30
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V09: Diagnostic radiopharmaceuticals
— V09E: Respiratory system diagnostic radiopharmaceuticals
— V09EX: Other respiratory system diagnostic radiopharmaceuticals in atc
— V09EX02: Xenon (127xe) gas
HCPCS
No data
Clinical
Clinical Trials
91 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Vulvovaginal candidiasisD002181EFO_0007543B37.31335111
Bacterial vaginosisD016585EFO_0003932111115
CandidiasisD002177B37—121—4
Invasive fungal infectionsD000072742———123
OnychomycosisD014009B35.1———112
Hyperlipoproteinemia type iiD006938EFO_0004911E78.00———1—1
BurnsD002056T30.0———1—1
Atopic dermatitisD003876EFO_0000274L20———1—1
Eczematous skin diseasesD017443———1—1
Chronic kidney failureD007676EFO_0003884N18.6———1—1
Show 2 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MycosesD009181B35-B49—23—26
OtomycosisD059249—23—26
Oral candidiasisD002180EFO_0007406B37.0—12—14
Tinea pedisD014008EFO_0007512B35.33—1——4
Hiv infectionsD015658EFO_0000764B20——2—13
TineaD014005EFO_0007510B35.4——2——2
Tinea crurisD000084002B35.6—11——2
Denture stomatitisD013282EFO_1000893K12.1—11——2
Intraabdominal infectionsD059413——1——1
FolliculitisD005499—11——1
Show 4 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Invasive pulmonary aspergillosisD055744B44.0—1——23
Sickle cell anemiaD000755EFO_0000697D5711——12
Myelodysplastic syndromesD009190D46—1——12
StomatitisD013280EFO_1001904K12.1—2———2
NeoplasmsD009369C80—1———1
LeukemiaD007938C95—1———1
Hematologic neoplasmsD019337—1———1
Graft vs host diseaseD006086D89.81—1———1
Kidney diseasesD007674EFO_0003086N0811———1
Kidney transplantationD01603011———1
Show 7 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1———12
Myeloid leukemia acuteD015470C92.01———12
EndometriosisD004715EFO_0001065N801————1
HivD006678O98.71————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Invasive candidiasisD058365EFO_1001283B37————11
Type 1 diabetes mellitusD003922EFO_0001359E10————11
Invasive hydatidiform moleD002820D39.2————11
FusariosisD060585EFO_1001795————11
HypercholesterolemiaD006937HP_0003124————11
Corneal ulcerD003320H16.0————11
SepsisD018805A41.9————11
Laser therapyD053685————11
Lichen planusD008010L43————11
RecurrenceD012008————11
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameXENON XE 127
INN—
Description
Xenon xe 127 is a small molecule pharmaceutical. Xenon xe 127 was first approved as Xenon xe 127 on 1982-10-01.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
[127Xe]
Identifiers
PDB—
CAS-ID13994-19-9
RxCUI—
ChEMBL IDCHEMBL1200673
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID—
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 289 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,748 adverse events reported
View more details